Global Partners L.P. logo

Global Partners L.P. (GLP)

Market Closed
10 Jul, 20:00
NYSE NYSE
$
52. 51
+0.3
+0.57%
$
1.79B Market Cap
12.15 P/E Ratio
2.38% Div Yield
27,100 Volume
3.9 Eps
$ 52.21
Previous Close
Day Range
51.06 52.85
Year Range
37 60
Want to track GLP and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 21 days
Global Partners (GLP), a Top Stock to Buy Amid the Spike in Oil Prices

Global Partners (GLP), a Top Stock to Buy Amid the Spike in Oil Prices

Operating one of the largest terminal networks of refined petroleum products in the Northeastern United States, Global Partners (GLP) is an appealing stock to consider amid the sharp spike in crude oil prices.

Zacks | 3 weeks ago
Modular Medical to Present Data from Study Examining Pump Delivery of a GLP-1R Agonist at the ADA 85th Scientific Sessions

Modular Medical to Present Data from Study Examining Pump Delivery of a GLP-1R Agonist at the ADA 85th Scientific Sessions

SAN DIEGO, CA / ACCESS Newswire / June 16, 2025 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to meet the needs of "almost-pumpers" with its user-friendly and affordable design, is pleased to announce its participation in the American Diabetes Association ("ADA") 85th Scientific Sessions, taking place June 20-23, 2025, at the McCormick Place Convention Center in Chicago, Illinois. The Company will feature a poster, number 783-P, titled "Elucidating the potential benefit of pump-delivered subcutaneous GLP-1R agonist: an exploratory study in the diet-induced obese mouse," to be presented by David Maggs, MD, FRCP during the General Poster Session on Sunday, June 22, 2025, from 12:30pm to 1:30pm in the Poster Hall.

Accessnewswire | 3 weeks ago
iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment

iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment

iBio nominates IBIO-610 as development candidate for its first-in-class Activin E antibody New study aims to evaluate the half-life of IBIO-610 in obese, elderly non-human primates (NHP) and assess early signs of efficacy on fat reduction and body composition Mouse study shows IBIO-610 alone drives an overall body weight loss of 8.9%*, and prevents weight regain following GLP-1 treatment in obese mice, results of which will be presented at ADA on Monday June 23 rd SAN DIEGO, June 16, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, today announced the initiation of a NHP study for its Activin E engineered antibody candidate, now named IBIO-610. This preclinical study will evaluate the pharmacokinetics and early signs of efficacy of IBIO-610 in obese and elderly NHPs, including its impact on fat and body composition.

Globenewswire | 3 weeks ago
Fractyl Health to Present New Preclinical Data from its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform at the American Diabetes Association's 85th Scientific Sessions

Fractyl Health to Present New Preclinical Data from its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform at the American Diabetes Association's 85th Scientific Sessions

BURLINGTON, Mass., June 13, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company), a metabolic therapeutics company focused on pattern-breaking approaches to treat the root causes of obesity and type 2 diabetes (T2D), today announced it will present a poster of new preclinical data from its Rejuva Smart GLP-1 pancreatic gene therapy platform at the American Diabetes Association's (ADA) 85th Scientific Sessions being held June 20-23, 2025, in Chicago, Illinois.

Globenewswire | 3 weeks ago
Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule

Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule

Oral DehydraTECH-liraglutide showed a pronounced reduction in adverse events (“AEs”) as compared to injected liraglutide (Saxenda®)    Lexaria has now demonstrated, in distinct human clinical studies, clear reductions in AEs utilizing its patented DehydraTECH technology with all of the three major GLP-1 drugs sold in the world today: liraglutide, semaglutide and tirzepatide

Thenewswire | 4 weeks ago
Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule

Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule

Oral DehydraTECH-liraglutide showed a pronounced reduction in adverse events (“AEs”) as compared to injected liraglutide (Saxenda(R))  Lexaria has now demonstrated, in distinct human clinical studies, clear reductions in AEs utilizing its patented DehydraTECH technology with all of the three major GLP-1 drugs sold in the world today: liraglutide, semaglutide and tirzepatide  KELOWNA, BC / ACCESS Newswire / June 11, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce that human study GLP-1-H25-5 (the "Study") which compared oral capsules of DehydraTECH-liraglutide to injected Saxenda®-branded liraglutide has been successfully completed with partial results now available. In distinct clinical human studies, Lexaria has now demonstrated clear reductions in AEs utilizing oral DehydraTECH versions of all three of the major GLP-1 drugs sold in the world today: liraglutide, semaglutide, and tirzepatide.

Accessnewswire | 4 weeks ago
Omada Health IPO to Price at $19 a Share as GLP-1s Fuel Interest

Omada Health IPO to Price at $19 a Share as GLP-1s Fuel Interest

Omada Health is making its public-market debut, propelled by Americans' renewed focus on how weight affects physical health.

Wsj | 1 month ago
Lilly's Jake Van Naarden: Lilly's success with GLP-1's allows us to reinvest in oncology

Lilly's Jake Van Naarden: Lilly's success with GLP-1's allows us to reinvest in oncology

CNBC's Angelica Peebles sits down with Lilly's Head of Oncology, Jake Van Naarden, to discuss what's next in Lilly's oncology pipeline and what Lilly is changing about its clinical trials to make them easier for patients to participate in.

Youtube | 1 month ago
Novo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock Has More Upside?

Novo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock Has More Upside?

With VKTX surging on clinical results and NVO investing to cement market share, investors face a high-stake GLP-1 showdown.

Zacks | 1 month ago
Novo Nordisk's GLP-1 lead narrows, but long-term thesis still holds

Novo Nordisk's GLP-1 lead narrows, but long-term thesis still holds

A fresh physician poll has revived debate over the shifting balance of power in the weight-loss drug market. According to Deutsche Bank, the snapshot shows a marginal swing in favour of Eli Lilly and Co's (NYSE:LLY) Zepbound over Novo Nordisk's (NYSE:NVO) Wegovy.

Proactiveinvestors | 1 month ago
NorthStrive Biosciences Announces Completion of Phase I Strategic Review for EL-22 Targeting Muscle Loss Associated with GLP-1 Weight Loss Drugs and Age-Related Sarcopenia

NorthStrive Biosciences Announces Completion of Phase I Strategic Review for EL-22 Targeting Muscle Loss Associated with GLP-1 Weight Loss Drugs and Age-Related Sarcopenia

NorthStrive Biosciences Announces Completion of Phase I Strategic Review for EL-22 Targeting Muscle Loss Associated with GLP-1 Weight Loss Drugs and Age-Re

Globenewswire | 1 month ago
CheqUp and WeightWatchers Announce Strategic Partnership to Support Growing Use of GLP-1 Medications in the UK

CheqUp and WeightWatchers Announce Strategic Partnership to Support Growing Use of GLP-1 Medications in the UK

Partnership Provides CheqUp Members Access to WeightWatchers' Proven GLP-1 Companion Programme to Aid in Achieving Superior and Sustainable Results Partnership Provides CheqUp Members Access to WeightWatchers' Proven GLP-1 Companion Programme to Aid in Achieving Superior and Sustainable Results

Globenewswire | 1 month ago
Loading...
Load More